Bio X Cell launches first ready-to-use anti-mouse trispecific checkpoint antibody for preclinical research
PD‑L1, TIGIT, and LAG3 trispecific antibody enables simultaneous in vivo analysis of multiple immune checkpoint pathways
9 Jun 2026Product news
Bio X Cell has launched the first commercially available ready-to-use anti-mouse PD-L1 × TIGIT × LAG3 trispecific antibody for preclinical research, providing immuno-oncology scientists with a new in vivo tool to study combinatorial immune checkpoint biology in standard mouse models.
This tetravalent trispecific antibody format enables simultaneous interrogation of three complementary checkpoint pathways within a single experimental system, helping researchers explore T-cell exhaustion, immune suppression, and combinatorial checkpoint blockade while reducing variability and experimental complexity.
Advancing combinatorial checkpoint biology in vivo
The anti-mouse PD-L1 × TIGIT × LAG3 trispecific antibody is designed to reflect the inherently combinatorial nature of checkpoint biology. By bringing PD-L1, TIGIT, and LAG3 together in one reagent, the format allows investigators to evaluate coordinated checkpoint interactions and mechanisms of T-cell exhaustion and immune suppression in a single in vivo system.
As LAG3 gains increasing clinical validation and TIGIT combinations continue to be explored across oncology programs, the demand for preclinical tools that mirror these complex therapeutic strategies has grown. This trispecific antibody supports studies of combinatorial checkpoint blockade without the added variability and logistical burden associated with multi-agent dosing regimens.
“Checkpoint biology is inherently combinatorial, and researchers increasingly need tools that reflect that complexity,” said Kaitlyn Bushey, Director of Development and Strategic Alliances at Bio X Cell. “This trispecific format brings PD-L1, TIGIT, and LAG3 together within a single in vivo system, expanding the experimental approaches available for studying checkpoint interactions.”
Engineered for standard mouse models and in vivo-ready quality
The PD-L1 × TIGIT × LAG3 trispecific antibody was recombinantly engineered with a murine IgG2a constant region to ensure compatibility with standard mouse models commonly used in preclinical immuno-oncology research.
The antibody is manufactured to Bio X Cell’s in vivo-ready quality standards, including:
- Ultra-pure formulations
- Carrier-free preparations
- Low endotoxin levels
These quality attributes are designed to minimize reagent-driven variability and support reproducible in vivo studies, giving research teams greater confidence in their checkpoint biology data.
Expanding beyond monoclonal antibodies to advanced recombinant formats
The launch of the PD-L1 × TIGIT × LAG3 trispecific antibody marks the latest example of Bio X Cell’s approach to defining in vivo-ready antibody standards as research demands evolve. By expanding beyond traditional monoclonal antibodies into advanced recombinant formats and offering custom engineering capabilities, Bio X Cell is enabling researchers to investigate increasingly complex biological questions across modern preclinical workflows.
Together, these catalog and custom capabilities provide a unified path from early mechanistic discovery through advanced multispecific development. This continuity in quality, production, and experimental design helps research teams streamline their preclinical workflows and maintain consistency from initial target validation through sophisticated multispecific antibody studies.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Frequently asked questions
What is Bio X Cell’s anti-mouse PD-L1 × TIGIT × LAG3 trispecific antibody and how does it advance preclinical immuno-oncology research?
Bio X Cell’s anti-mouse PD-L1 × TIGIT × LAG3 trispecific antibody is the first commercially available ready-to-use trispecific antibody for preclinical research. This tetravalent reagent targets three immune checkpoint pathways — PD-L1, TIGIT, and LAG3 — within a single in vivo system. It enables immuno-oncology scientists to study combinatorial checkpoint biology, T-cell exhaustion, and immune suppression in standard mouse models while reducing variability and experimental complexity compared with multi-agent dosing regimens.
How does the PD-L1 × TIGIT × LAG3 trispecific antibody support studies of combinatorial checkpoint blockade and T-cell exhaustion in standard mouse models?
The PD-L1 × TIGIT × LAG3 trispecific antibody is designed to reflect the inherently combinatorial nature of checkpoint biology by bringing three complementary checkpoints together in one reagent. This format allows investigators to evaluate coordinated checkpoint interactions and mechanisms of T-cell exhaustion and immune suppression in a single in vivo system.
As LAG3 gains clinical validation and TIGIT combinations are explored across oncology programs, this antibody provides a preclinical tool that mirrors complex therapeutic strategies without the added variability and logistical burden of separate checkpoint-blocking agents.
What engineering and quality features make Bio X Cell’s PD-L1 × TIGIT × LAG3 trispecific antibody suitable for in vivo checkpoint biology studies?
The PD-L1 × TIGIT × LAG3 trispecific antibody is recombinantly engineered with a murine IgG2a constant region to ensure compatibility with standard mouse models commonly used in preclinical immuno-oncology research.
It is manufactured to Bio X Cell’s in vivo-ready quality standards, including ultra-pure formulations, carrier-free preparations, and low endotoxin levels. These attributes are intended to minimize reagent-driven variability, support reproducible in vivo studies, and provide continuity in quality and experimental design from early mechanistic discovery through advanced multispecific antibody development.